Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 4, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 6, 2026
CFOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000310158-26-000038
Filed / recorded
Feb 6, 2026, 9:13 PM UTC
Added to OQRO
Oct 2, 2026, 3:52 AM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Merck & Co., Inc.
Issuer CIK
310158
Ticker
MRK
Reporting person
Caroline Litchfield
Relationship
Officer
Officer title
EVP & CFO
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Feb 4, 2026
Transaction code
M
Shares / units
41,997
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
